🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 45 of 173

  1. US 10865387

    Methods of obtaining pancreatic endocrine cells

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10864256

    Methods and compositions for improved cognition

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10864272

    Scintillator nanocrystal-containing compositions and methods for their use

    Expires Mon Dec 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10858432

    Antibodies specific to glycosylated PD-1 and methods of use thereof

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10858323

    HDAC inhibitors for the treatment of diabetic peripheral neuropathy

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10857139

    Substituted diazaspiroalkanes as androgen receptor modulators

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10857140

    K-Ras modulators

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10857106

    Methods and products for treating and/or delaying onset of dysplastic lesions

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10857382

    Compositions and methods for treating and preventing chronic pain

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10858396

    HER2 peptide regents and methods

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10858410

    Glycosylated peptides with pseudoproline residues and having enhanced half-lives and ability to cross the blood brain barrier

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10858416

    Methods and compositions for modification of a HLA locus

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10858338

    Inhibitors for soluble epoxide hydrolase (SEH) and fatty acid amide hydrolase (FAAH)

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10857165

    Skeletal removal of bisphosphonates

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10858627

    Regulation of mesodermal specification

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10857185

    Compositions and methods for reprogramming non-neuronal cells into neuron-like cells

    Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10849965

    H3.3 CTL peptides and uses thereof

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10851367

    Tissue-specific genome engineering using CRISPR-Cas9

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10851173

    Anti-OX40 antibodies and methods of using the same

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10851463

    Membrane template synthesis of microtube engines

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10851110

    Heterocyclic inhibitors of PTPN11

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10851072

    Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10849936

    Compositions and methods for C. difficile treatment

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10850011

    Hydrogel membrane for adhesion prevention

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10849988

    Hydrogel for engineered immune response to D-chirality peptides

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10849875

    Cancer specific lipid targeted peptidomimetics

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10849910

    Use of H3K9me3 modulation for enhancing cognitive function

    Expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10842743

    Modified hyaluronic acid hydrogels and proteins for the time-controlled release of biologic agents

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10844052

    LLS compounds for treatment of cancer

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10842835

    Oncolytic vaccinia virus mutants and using same for cancer treatment

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10842791

    Small molecule inhibitors of EGFR and PI3K

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10842814

    Use of low dose arsenic for preserving genomic integrity

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10842664

    Skin-like condoms having active ingredients to enhance a male erection and a female arousal

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10844102

    Peptides, compositions, and methods for stimulating subcutaneous adipogenesis

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10844357

    Engineered respiratory syncytial viruses with control of cell-to-cell virus transmission for enhanced safety of live virus vaccines

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10845366

    Predictive markers for polyamine inhibitor cancer therapies

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10842908

    Polyphosphate-functionalized inorganic nanoparticles as hemostatic compositions and methods of use

    Expires Mon Nov 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10837001

    Cardiomyocyte maturation platform

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10835609

    Hydrogels for delivery of therapeutic compounds

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10835614

    Poly(diol fumarates) and poly(diol fumarate-co-succinates)

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10836808

    Binding-triggered transcriptional switches and methods of use thereof

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10836720

    Inhibitors of integrin alpha 5 beta 1 and methods of use

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10835513

    Methods and treatments for the learning and memory deficits associated with Noonan syndrome

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10836827

    Antibodies specific to glycosylated PD-L1 and methods of use thereof

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10837961

    Molecular imprinted colored silica beads

    Expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10833330

    Sulfur composites and polymeric materials from elemental sulfur

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10828265

    Formulations of propranolol and analogs as an amorphous melt or ionic liquid for transdermal drug delivery

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10829536

    Methods of promoting CNS neuronal repair by inhibiting LRP-1

    Expires Mon Nov 05 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.